Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis

A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia

(2020) Stephanie Niman et al.   American Journal of Cardiovascular Drugs

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

(2019) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials

(2019) Xiaolin Wang et al.   Kardiologia Polska

What’s new in lipid lowering therapies in diabetes?

(2019) Yee‐Ming Cheung et al.   INTERNAL MEDICINE JOURNAL

ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials

(2019) M. Ruscica et al.   EXPERT OPINION ON PHARMACOTHERAPY

Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized, placebo-controlled trial

(2019) Narendra D. Lalwani et al.   Journal of Clinical Lipidology

Recent advances in synthetic pharmacotherapies for dyslipidaemias

(2019) Cesare R Sirtori et al.   European Journal of Preventive Cardiology

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance

(2019) Ulrich Laufs et al.   Journal of the American Heart Association

Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial

(2019) Omar Sheikh et al.   Cardiovascular Diabetology

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy

(2019) Christie M Ballantyne et al.   European Journal of Preventive Cardiology

An update on pharmacotherapies in diabetic dyslipidemia

(2019) Manasvi Gupta et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina

(2019) Chiara Caselli et al.   Cardiovascular Diabetology

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

(2019) Kausik K. Ray et al.   Cardiovascular Diabetology

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease

(2019) Anne C. Goldberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bempedoic Acid for Lowering LDL Cholesterol

(2019) Michael C. Honigberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

(2018) Christie M. Ballantyne et al.   ATHEROSCLEROSIS

Bempedoic Acid (ETC-1002)

(2018) Anum Saeed et al.   CARDIOLOGY CLINICS

Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials

(2018) Lauren L. O’Mahoney et al.   Cardiovascular Diabetology

Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association

(2018) Emelia J. Benjamin et al.   CIRCULATION

Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

(2018) Peter W.F. Wilson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus

(2017) Concepción Peiró et al.   Frontiers in Pharmacology

Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy

(2016) Christie M. Ballantyne et al.   AMERICAN JOURNAL OF CARDIOLOGY

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

(2016) Paul D. Thompson et al.   Journal of Clinical Lipidology

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance

(2015) Paul D. Thompson et al.   Journal of Clinical Lipidology

Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus

(2014) Maria J. Gutierrez et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase

(2014) Sergey Filippov et al.   CURRENT OPINION IN LIPIDOLOGY

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2013) Alessandro Liberati   ANNALS OF INTERNAL MEDICINE

Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

(2013) Christie M. Ballantyne et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism

(2012) Stephen L. Pinkosky et al.   JOURNAL OF LIPID RESEARCH

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal